Motilal Oswal Alternates Invests Rs 450 Crore in Mega Fine Pharma for Majority Stake

Motilal Oswal Alternates announced a Rs 450-crore investment in Mega Fine Pharma for a majority stake. The Sanghvi family also increased their stake. The investment aims to transform the API-focused company into a long-lasting institution by enhancing R&D and manufacturing capabilities and exploring inorganic growth opportunities.

Motilal Oswal Alternates has taken a significant step with its recent Rs 450-crore investment for a majority stake in Mega Fine Pharma.

The Sanghvi family, who are the promoters of the company, have also expanded their stakes, underlining their commitment to the pharmaceutical venture.

Established in 1995, Mega Fine Pharma operates USFDA-approved facilities in Nashik and Vapi, specializing in niche APIs. With the appointment of Shailesh Sanghvi as the managing director, the company aims to capitalize on Motilal Oswal's expertise in life sciences to drive its growth and secure new opportunities.

(With inputs from agencies.)